Microba Life Sciences Limited
Research Microba Life Sciences Limited (F3Y) on Bullrun: market cap EUR 17.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerF3Y
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 17.57M
- Financial periodFY2025
- RevenueAUD 15.67M
- Revenue growth29.6%
- Net income-AUD 14.94M
- Free cash flow-AUD 14.91M
- Gross margin47.5%
Valuation Snapshot
latest market cap is EUR 17.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 15.67M | -AUD 14.94M | -AUD 14.91M | 47.5% | -0.03 | AUD 11.74M | AUD 3.23M | AUD 32.49M |
| FY2024 | AUD 12.09M | -AUD 19.94M | -AUD 19.95M | 48.8% | -0.05 | AUD 20.89M | AUD 1.58M | AUD 41.22M |
| FY2023 | AUD 5.42M | -AUD 12.68M | -AUD 15.43M | 49.4% | -0.04 | AUD 32.04M | AUD 1.14M | AUD 38.57M |
| FY2022 | AUD 4.69M | -AUD 11.47M | -AUD 12.32M | 50.5% | -0.05 | AUD 30.58M | AUD 1.33M | AUD 33.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 17.57M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Microba Life Sciences Limited's market cap?
Microba Life Sciences Limited's market capitalization is EUR 17.57M.
What does Microba Life Sciences Limited do?
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome.